Clinical Trials Logo

Clinical Trial Summary

Tick-borne Encephalitis (TBE) can be prevented by vaccine. Vaccine failure, defined as a case of TBE regardless of previous vaccination, has been described and seems to be more predominant with increasing age, suggesting a less effective immune response following with increasing age. In fact previous studies has shown a reduced antibody response in elderly individuals compared to younger when vaccinated against TBE. As a result, in Sweden, an extra vaccine dose has been recommended during the primary vaccine schedule to individuals > 50 years of age. This alternative vaccine schedule has not been tested. The investigator aim to test if an extra vaccine dose in the primary vaccine schedule for those > 50 years of age improves the immune response and offers a corresponding immunity to younger individuals following TBE vaccination.


Clinical Trial Description

n/a


Study Design


Related Conditions & MeSH terms


NCT number NCT04573205
Study type Interventional
Source Region Örebro County
Contact Anja Rosdahl
Phone +46196021157
Email anja.rosdahl@regionorebrolan.se
Status Not yet recruiting
Phase Phase 4
Start date January 2024
Completion date January 2025

See also
  Status Clinical Trial Phase
Recruiting NCT04460235 - Immunogenicity of an Anti-pneumococcal Combined Vaccination in Acute Leukemia or Lymphoma Phase 4
Recruiting NCT04543877 - WHNRC (Western Human Nutrition Research Center) Fiber Intervention Study Early Phase 1
Completed NCT00401505 - Rubella Susceptibility in Multiparous Women
Recruiting NCT05054621 - Immunogenicity of COVID-19 Vaccine on Heterologous Schedule Phase 2
Completed NCT05083065 - Evaluation of Menstrual Irregularities and Abnormal Uterine Bleeding After Covid-19 Vaccine
Recruiting NCT05085145 - Immunogenicity and Safety of COVID-19 Vaccine in People Living With HIV Phase 4
Completed NCT05046548 - This is a Double-blind, Placebo-controlled, Randomized Study of the Tolerability, Safety and Immunogenicity of an Inactivated Whole Virion Concentrated Purified Vaccine (CoviVac) Against Covid-19 Phase 1/Phase 2
Completed NCT01961947 - Study of ASP7374, Cell-culture-derived Influenza Vaccine Phase 3
Completed NCT01961960 - A Study to Evaluate Intramuscular ASP7374 Phase 3
Completed NCT00401700 - Influenza Vaccine Postpartum Questionnaire
Completed NCT03300050 - Safety and Immunogenicity of a Live-attenuated Universal Flu Vaccine Followed by an Inactivated Universal Flu Vaccine Phase 1
Completed NCT01015703 - Open-label Safety and Tolerability Study of CoVaccine HTâ„¢ in Healthy Volunteers Phase 1
Completed NCT00560066 - Safety of a Influenza Vaccine Produced Either in Mammalian Cell Culture or in Embryonated Hen Eggs in Adults and Elderly With and Without Underlying Medical Conditions, and Immunogenicity in a Subset of Subjects With Underlying Medical Conditions Phase 4
Active, not recruiting NCT05099965 - Trial to Evaluate the Safety and Immunogenicity of a Modified Vaccinia Ankara (MVA)-Based Anti-Cytomegalovirus (CMV) Vaccine (Triplex®) Phase 2
Recruiting NCT04638985 - Evaluation of Immunogenicity and Safety of Combined Immunization of sIPV, DTaP and MMR Phase 4
Recruiting NCT06136832 - Pneumonia Vaccine Education Intervention Study N/A
Active, not recruiting NCT04741828 - Persistence and Long-Term Protection of Vi Antibodies Induced by Vi-DT Conjugate Vaccines in Indonesian Phase 2/Phase 3
Completed NCT05083039 - Observational Program, Study the Preventive Efficacy of the BiVac Polio Vaccine Against the Incidence of Acute Respiratory Infections, Including COVID-19
Completed NCT03714737 - Immunogenicity and Safety of Bivalent Meningococcal Serogroups A and C Tetanus Toxoid Conjugate Vaccine in Chinese Phase 3
Completed NCT04664309 - Understanding Immunity to the COVID-19 Vaccines